A novel dual DYRK1A/B inhibitor for the treatment of type 1 diabetes
BackgroundType 1 diabetes (T1D) is an autoimmune disease that leads to the progressive destruction of pancreatic β cells, resulting in insulin deficiency and hyperglycemia. Current treatments focus on insulin replacement, but novel therapeutic approaches targeting β cell regeneration are needed. Dua...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2025-10-01
|
| 叢編: | Frontiers in Pharmacology |
| 主題: | |
| 在線閱讀: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1657042/full |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|